Regeneron 8-K: Executive Comp/Officer Changes Reported Jan 26

TL;DR

**Regeneron filed an 8-K about executive changes and compensation, but the details aren't public yet.**

AI Summary

Regeneron Pharmaceuticals, Inc. filed an 8-K on January 31, 2024, reporting an event that occurred on January 26, 2024. This filing is categorized under 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers'. While the filing indicates a change in executive or director compensation, the specific details of these arrangements or personnel changes are not provided within the accessible text. This matters to investors because changes in executive compensation or leadership can signal shifts in company strategy, financial health, or governance, potentially impacting future stock performance.

Why It Matters

Changes in executive compensation or officer appointments can reflect strategic shifts or performance incentives, directly influencing investor confidence and the company's future direction.

Risk Assessment

Risk Level: medium — The filing indicates changes in executive compensation or officers, which can be either positive or negative, but the lack of specific details creates uncertainty.

Analyst Insight

A smart investor would monitor Regeneron's subsequent filings or press releases for specific details on the reported executive changes and compensation arrangements, as these could provide clearer insights into the company's strategic direction and financial health.

Key Numbers

• $0.001 — par value per share (the stated par value for Regeneron's Common Stock)
• 000-19034 — Commission File Number (Regeneron's SEC file number)
• 13-3444607 — I.R.S. Employer Identification No. (Regeneron's IRS EIN)

Key Players & Entities

• REGENERON PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
• NASDAQ Global Select Market (company) — the exchange where Regeneron's Common Stock is registered
• $0.001 (dollar_amount) — par value per share of Common Stock

Forward-Looking Statements

• Further details regarding the specific compensatory arrangements or officer changes will be disclosed in a subsequent filing or announcement. (REGENERON PHARMACEUTICALS, INC.) — medium confidence, target: 2024-03-31

FAQ

Key Financial Figures

• $0.001 — h registered Common Stock – par value $0.001 per share REGN NASDAQ Global Select M
• $660,000 — ore's 2024 base salary was increased to $660,000 and he was granted an equity award unde
• $5,000,000 — with a target grant date fair value of $5,000,000. The equity award was granted in Decemb

Filing Documents

• tm244671d1_8k.htm (8-K) — 25KB
• 0001104659-24-008807.txt ( ) — 193KB
• regn-20240126.xsd (EX-101.SCH) — 3KB
• regn-20240126_lab.xml (EX-101.LAB) — 33KB
• regn-20240126_pre.xml (EX-101.PRE) — 22KB
• tm244671d1_8k_htm.xml (XML) — 3KB

02

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 26, 2024, based on a previously disclosed Chief Financial Officer succession plan, Regeneron Pharmaceuticals, Inc. (" Regeneron " or the " Company ") appointed Christopher Fenimore, currently the Company's Senior Vice President, Controller, as Senior Vice President, Finance and Chief Financial Officer to succeed the current Chief Financial Officer, Robert E. Landry, who is retiring. On the same day, the Company also appointed Jason Pitofsky, currently the Company's Vice President, Accounting and Financial Reporting, as Vice President, Controller. Each such appointment will be effective as of the day after Regeneron files its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (expected to occur on February 5, 2024). Mr. Fenimore, 53, has served as Senior Vice President, Controller since January 2021. He previously served as Vice President, Controller from March 2017 to December 2020, as Vice President, Deputy Controller from January 2017 to March 2017, and as Vice President, Financial Planning from January 2012 to December 2016. Prior to joining the Company in 2003, he was Vice President, Finance for a biotechnology start-up and worked in other healthcare industry-focused venture capital and investment banking roles. Mr. Fenimore started his career as an auditor at KPMG and is a Certified Public Accountant in the State of New York. Mr. Fenimore holds an M.A. in Biotechnology from Columbia University, an M.B.A. in Professional Accounting from Rutgers Business School, and a B.A. in Economics from Rutgers University. Mr. Pitofsky, 46, has served as Vice President, Accounting and Financial Reporting since January 2021. He previously served as Executive Director, Accounting and Financial Reporting from 2017 to 2020. Between 2011 and

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REGENERON PHARMACEUTICALS, INC. /s/ Joseph J. LaRosa Joseph J. LaRosa Executive Vice President, General Counsel and Secretary Date: January 31, 2024

View Full Filing

View this 8-K filing on SEC EDGAR